Results 131 to 140 of about 3,985,796 (312)
Out With the Old, in With the New: Age-Related D-Dimer Thresholds. [PDF]
O'Connor C, McIntyre C, Wynne C.
europepmc +1 more source
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
New age HCT conditioning regimens: what works and why? [PDF]
Ali N, Sandmaier BM.
europepmc +1 more source
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Finding value in the third year of cardiology fellowship in the new age of an accelerated pathway to electrophysiology. [PDF]
Haloot J.
europepmc +1 more source
New-age vaccine adjuvants, their development, and future perspective. [PDF]
Verma SK +6 more
europepmc +1 more source
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen +14 more
wiley +1 more source
New age GVHD prophylaxis regimens: what works for what donor and why. [PDF]
Gooptu M, Koreth J.
europepmc +1 more source
Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy. [PDF]
Prasad K, Cross RS, Jenkins MR.
europepmc +1 more source

